High-dose immunoablative chemotherapy with autologous haematopoietic cell support might be beneficial in the treatment of intractable forms of MS. We mobilised PBPC in 11 patients with secondary progressive MS and finally eight patients were grafted after high-dose BEAM chemotherapy with either in vitro or in vivo T cell depletion. Median EDSS and SNRS scores at the time of inclusion were 6.5 (6.5-7.5) and 56 (44-65), respectively. PBPC mobilisation was safe with no serious adverse effects, and without significant aggravation of disability. 
Patients and methods

Patient selection
The phase I/II clinical trial was approved by the local ethics committee. Each referred case was first reviewed by the Indication Committee which included a haematologisttransplantologist and two established neurologists with long-term experience in MS treatment. Once a case was unanimously approved by the Indication Committee, the ethics committee was informed. The individual steps of the whole procedure were described in detail to the patient and his/her family, and the patient signed an informed consent. Inclusion criteria were: (a) definite MS according to the Poser criteria, secondary progressive form; (b) deterioration of at least 1.5 on the Kurtzke Expanded Disability Status Scale (EDSS) 11 in the past year, clinically 6.0-7.5 EDSS; (c) failure of conventional therapy, including high-dose pulse methylprednisolone combined with either cyclophosphamide or mitoxantrone; (d) no serious internal organ dysfunction precluding transplantation (e) anti-HIV, HBsAg and anti-HCV negativity; (f) sufficient motivation and compliance; (g) age 18-55 years; and (h) signed informed consent.
From January 1998 until April 1999, 11 patients fulfilling the criteria were included in the trial. Pre-trial treatment of those patients varied extensively. All patients entered the trial on oral corticosteroids. Patient characteristics are included in Table 1 .
Stem cell mobilisation
Cyclophosphamide at a dose of 4 g/m 2 on day 1 followed by G-CSF (10 × filgrastim 7-10 g/kg, 1 × lenograstim 7 g/kg), subcutaneously from day 3 until the end of leukapheresis was used for PBPC mobilisation. Patients started leukapheresis once their leukocyte counts were in excess of 1.0 × 10 9 /l and their CD34 + cells exceeded 10/l. A target to harvest 6 × 10 6 CD34 + cells/kg of body weight (BW) was set. In patients where the target of 6 × 10 6 CD34 + cells/kg BW was not met ATG (Fresenius AG, Bad Homburg, Germany) was used as a form of in vivo depletion. Patients with less than 2 × 10 6 CD34 + cells/kg BW were excluded from the trial.
PBPC separation was performed using the Cobe Spectra (Lakewood, CO, USA) continuous blood flow cell separator, or the Haemonetics MCS 3P (Haemonetics SA, Nyon, Switzerland).
T cell depletion
T cell depletion ex vivo was performed on seven grafts. In five patients, a two-phase T depletion of the harvested PBPC was used. In the first phase, CD34
+ positive selection was carried out using the CEPRATE SC Stem cell Concentrator (CellPro, Bothell, WA, USA). The product underwent further T depletion using anti CD2/CD3 monoclonal mouse antibodies and e-rosettes (CLB, Amsterdam, The Netherlands) and the final product was analysed using flow cytometry for the number of CD34 + , CD3 + , CD2 + and CD56 + cells. When the CEPRATE SC system was no longer available, a new purging system, CliniMACS (Miltényi Biotec, Bergisch Gladbach, Germany) was used to purge the last two grafts. One graft, which was not sufficiently rich in CD34 + cells, did not undergo ex vivo T cell depletion. Instead, in vivo T cell depletion was performed using antithymocyte globulin (ATG) at a dose of 4 mg/kg BW on days +1 and +2 following PBPC re-infusion.
Immunological assays
One-and two-color immunophenotyping for flow cytometry analysis was performed on EDTA anticoagulated whole blood, PBPC leukapheresis product, and on the specimen from the purged PBPC product. The panel of monoclonal antibodies conjugated to one of the two fluorochromes, fluorescein isothiocyanate (FITC) or phycoerythrin (PE), included antibodies to HLA-DR, CD2, CD3, CD4, CD8, CD19, CD34, CD38, CD45RA, CD56, CD57 (Immunotech, Marseille, France). The quality control of the purged graft was performed using a flow cytometer Coulter XL (Hialeah, FL, USA 2 ) in all the rest 140 mg/m 2 on day −1. Progenitor cell thawing and re-infusion was performed on day 0. In one patient without ex vivo T cell depletion, ATG was given at a dose of 4 mg/kg BW on days +1 and +2.
G-CSF (Neupogen; Roche, Basel, Switzerland) was given from day +3 at a dose of 300 g s.c. until leukocyte numbers were in excess of 5.0 × 10 9 /l. IVIG (Flebogamma, Grifols, Spain) at a dose of 10 g i.v. was administered on days −7 and +7. Oral ciprofloxacin (2 × 500 mg), fluconazole (100 mg) and valacyclovir (2 × 500 mg) were administered from day 0.
Evaluation of toxicity and neurological findings
Adverse events occurring during the mobilisation and transplantation period were scored using the WHO grading system. Patients were assessed for non-neurological toxicity at the Department of Haematology between days +30 and +40. Patients were then followed and monitored by a haematologist every 3 months.
The Kurtzke EDSS (Expanded Disability Status Scale) and SNRS (Scripps Neurological Rating Scale) scoring systems were used to assess patient neurological status. 11, 12 This assessment was performed by one of the two neurologists, a member of the Indication Committee. Patients were evaluated upon entering the study (baseline score), after PBPC mobilisation, between days + 30 and + 40, and every 3 months thereafter. Aggravation of pre-existing symptoms or relapse following improvement was defined as an increase of 1.0 or more on the EDSS scale or loss of 10 and more points from baseline on the SNRS scale. Dis-ease stabilisation was defined as no change in patient symptoms compared to baseline, or as a change of less than 1.0 points in either direction on the EDSS, or 10 points on the SNRS scale, respectively.
MRI was performed on entry, and was scheduled 12, 18 and 24 months post transplant. Earlier MRI required the approval of the regulatory authorities.
Results
Stem cell mobilisation and harvest
Eleven patients underwent PBPC mobilisation. In seven of these, the stem cell harvest was sufficient for ex vivo T cell depletion. In two patients, PBPC harvests were not sufficient for graft purging. Finally, two patients were released from the study because of mobilisation failure. The median number of leukapheresis sessions was 3 (range 0-4 /kg BW). Mobilisation regimen toxicity was mild. Amelioration of neurological disability was noted in one case, with the patient improving from an EDSS of 6.5 to an EDSS of 5.5. Eight patients experienced fever that required i.v. antibiotics. Patient No. 7 had a poor harvest, and experienced prolonged cytopenia with longer-lasting fever and folliculitis that ultimately responded to broad-spectrum antibiotics. None of the patients had positive blood cultures. The median number of days spent in hospital was 15 (range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Mobilisation course and results are shown in Table 2 .
Transplant-related toxicity
Eight patients were transplanted using the BEAM conditioning regimen (see above). There were no transplantation-related deaths. Table 3 includes an overview of haematological recovery and toxicity.
Median leukocyte engraftment (ANC Ͼ0.5 × 10 9 /l) was 9 days post transplant (range 8-10 days). Median thrombo- After purging in purged grafts.
Bone Marrow Transplantation cyte engraftment (platelets Ͼ20 × 10 9 /l unsupported) was 11 days following re-infusion (range 9-14 days). Febrile neutropenia was noted in every patient. Gram positive bacteremia occurred in two patients, with a good response to antibiotics. There were two cases of WHO grade III oral mucositis and two cases of WHO grade III enteritis.
Late infectious complications following engraftment related to protracted suppression were noted in two patients. The first patient developed cellulitis of the left arm on day +40. This required re-admission and i.v. antibiotic administration. The second patient developed Herpes zoster 9 months post transplant and required i.v. administration of acyclovir with good response.
Disability changes
Median follow-up of transplanted patients was 8.5 months (range 1 to 16). Median EDSS and SNRS scores of transplanted patients at the entry were 6.5 (6.5-7.5) and 57 (44-65), respectively. Median EDSS and SNRS scores of the patients at the last follow-up were 6.5 (5.5-8.5) and 64 (39-73), respectively. During the transplantation regimen, and especially during febrile episodes, all patients reported a subjective deterioration of their mobility. However, no objective worsening more than 0.5 points on the EDSS scale was noted at that time. Upon discharge from the BMT unit no aggravation of more than 0.5 points on the EDSS scale was noted in any of the patients.
Finally, the originally progressive disease became stable in all the grafted patients but one. The first transplant patient improved markedly. Her EDSS and SNRS scores improved by 1.5 and 18 points, respectively. In another two patients, an improvement of 0.5 points on the EDSS and slight improvement on the SNRS score (less than 10 points) has been noted. In four grafted patients the EDSS score remains stable and their SNRS slightly improved (two patients) or remains stable (two patients). Most of the transplanted patients were able to reduce their dose of corticosteroids.
Patient No. 4 continues in progressive deterioration of her neurological disability. Despite the high-dose therapy she progressed in EDSS by 1.0 point and in SNRS by 5 points within 10 months. The outcome of all patients entering the study in EDSS and SNRS rating scores is listed in Table 4 .
MRI study
MRI findings are evaluable in seven patients at this time. Stable image, ie no new lesions of demyelinisation and no activity, was found in five patients. In one patient (No. 9) the size of several lesions decreased significantly with loss of gadolinium enhancement. In patient No. 4, several new lesions appeared, without gadolinium enhancement. MRI results are listed in Table 5 .
Immune reconstitution
Immune post-transplant reconstitution was monitored by studying the dynamics of individual T and B lymphocyte subpopulations in peripheral blood. No T cell function assessment in vitro was performed. Around day +50 post transplant, the ratio of CD4 + lymphocytes decreased, while that of CD8 + lymphocytes increased. This corresponded to a significant decrease of the immuno-regulatory index (IRI). This index increased around day +180 in one evaluable patient. In the other patients, the IRI remains very low. The proportion of CD4 + CD45RA + cells (naive T cells) decreased and was very low during 2 months after trans- Table 4 Outcome of all patients entered in the study 
Discussion
High-dose immunosuppressive therapy with allogeneic, autologous or no haematopoietic progenitor rescue has been proposed for the management of intractable autoimmune diseases in humans. [1] [2] [3] [4] [5] 13, 14 Experiments on animal models and the effect of myeloablative-immunoablative treatment in patients with concomitant haematological and autoimmune disease (AID) constitute the background for such a new approach. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Based on animal models and experience in humans, allogeneic haematopoietic cell transplantation would represent the best option to cure poor risk AID. 14, 25, 26 However, allogeneic BMT still carries a risk of significant mortality and morbidity which is unacceptable in the treatment of AID. Therefore, the autologous approach was recommended for initial pilot studies in human AID. 5, 27 The controversial issue in the autologous setting remains
Immunoablative treatment in multiple sclerosis T Kozák et al 529 Table 5 Results of MRI studies Examination with gadolinium at baseline was not performed in all patients. b Follow-up MRI was not approved by regulatory authorities earlier than 12 months after baseline. whether the prolonged immunodepression after BMT (PBPC transplantation) is responsible for disease arrest, or whether there occurs a re-setting of the immune system with shift to self-tolerance. Data from animal models support the idea of immune system re-programming after an autologous BMT. It was inferred from those experiments, that the reconstituting lymphocytes developing from the early progenitor haematopoietic cell acquired de novo
Bone Marrow Transplantation immunocompetence and became unresponsive to 'self' by similar mechanisms that occur during the immune system ontogeny. 16 The limited experience with high-dose immunosuppression and stem cell support in human AID offers no conclusive answer to this question. Moreover, in human T cells, in contrast to B cells, recapitulation of ontogeny after BMT has not been documented, so far. 28 The first results of autologous bone marrow or PBPC 29, 30 In both studies, most of the patients enjoyed stabilisation of their otherwise rapidly progressive disease, and improved subjectively in their SNRS score. Nearly half of the patients from Thessaloniki improved also in their EDSS. 29 Like the investigators in Thessaloniki, we found the BEAM conditioning attractive because of (a) good lympholytic effect and (b) the possibility of BCNU and Ara-C exerting their effect across the blood-brain barrier. We were afraid of the neurotoxic effect of TBI, reported in animal studies, so we did not use it as part of the conditioning regimen. However, the initial results of the Chicago study show no such adverse effect in humans. 30 We did not think that high-dose cyclophosphamide alone would be effective enough for our patients with MS, as most of them were pretreated with pulses of intermediate-dose cyclophosphamide (1-2 g i.v.) as part of conventional treatment, without any effect. However, one patient in our group improved her disability after the mobilisation with cyclophosphamide 4 g/m 2 and G-CSF.
T cell depletion is another discussed topic. Both residual autoreactive T lymphocytes which survived conditioning and lymphocytes in the graft are claimed to be responsible for relapses of AID in animal models. 25, 31 Early relapses after unmanipulated autologous stem cell transplantation in humans support this theory. 32 However, early relapses after autologous transplantation with T cell depleted grafts were reported. 33, 34 We found the arguments for T cell depletion compelling and included the procedure in our study design. In cases where we performed ex vivo purging, we achieved T celldepleted grafts containing 0 to 3.5 × 10 4 CD3 + cells/kg BW without serious infectious complications, so far. Immunophenotyping of peripheral lymphocytes is an easy and well standardized procedure to assess immune reconstitution following engraftment. However, it does not necessarily reflect all functional changes of the system. 35, 36 After transplantation with unmanipulated PBPC graft, only CD4 + CD45RA + (naive helper cells) undergo thymic dependent regeneration. They recover much more slowly than their memory counterparts (CD4 + CDRO + cells), which recover via the extrathymic pathway. Follow-up of immune recovery in our study is short and we can confirm, so far, that the relative counts of CD4 + cells and CD4/CD8 ratio are low in all patients but patient No. 1.
To this day, most of the results published on high-dose immunoablative therapy in AID deal with autologous haematopoietic cell rescue. Recently, a discussion has begun about two new approaches in high-dose chemotherapy, both attractive for treatment of AID. The first involves nonmyeloablative conditioning regimens which enable both durable engraftment of allogeneic donor blood stem cells and induction of graft-versus-leukemia (GVL) or graft-versus-autoimmunity (GVA) effects mediated by donor lymphocytes. Initial results are encouraging, but longer follow-up is needed. 37 The second emerging approach is an immunoablative conditioning which does not in fact require stem cell rescue. 13 These results are also encouraging and they may serve as evidence that deep immunosuppression is the only factor responsible for the effect seen after high-dose immunoablative treatment with stem cell rescue. However, the sensitivity of bone marrow to high-dose cyclophosphamide may be individual. Patient No. 7 in our study spent 26 days in hospital during PBPC mobilisation with 4 g/m 2 of cyclophosphamide + G-CSF because of prolonged febrile neutropenia (14 days ANC Ͻ0.5 × 10 9 /l).
In conclusion, our results show that a high-dose immunoablative regimen with stem cell support is feasible in patients with poor risk MS. Further clinical, immunological and MRI follow-up will continue.
